Corbus Pharmaceuticals stock rose 4.39 percent to USD 4.52 on October 16

Published on 10/17/2026 at 20:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Next earnings are scheduled for November 11, 2026. Corbus Pharmaceuticals stock stood at USD 4.52 on October 16, 2026, up 4.39 percent versus Nasdaq's prior close.

Stock rises on Nasdaq

Corbus Pharmaceuticals finished the October 16, 2026 session above its previous close.
In the second quarter of 2026, net loss reached USD 35.04 million and diluted earnings per share were minus USD 1.81.
Corbus Pharmaceuticals stock stood at USD 4.52 on October 16, 2026 at 4:00 p.m. ET, up 4.39 percent versus the Nasdaq prior close.
The next earnings report is scheduled for November 11, 2026.

CRBP, US21833P3010, Illustration mit AI erstellt.

Corbus Pharmaceuticals stock rose 4.39 percent to USD 4.52 on Nasdaq on October 16, 2026, closing USD 0.19 above the prior close of USD 4.33. The session was the company's strongest market signal in the latest available trading data. EarningsToday lists November 11, 2026 as the next scheduled earnings date.

Second-quarter loss sets the backdrop

Corbus reported a net loss of USD 35.04 million in the second quarter of 2026, while diluted earnings per share were minus USD 1.81. Revenue was USD 0 for the period. Investing.com reported that adjusted and GAAP earnings per share both came in at minus USD 1.81, against a consensus estimate of minus USD 1.30, a shortfall of 39.23 percent. The comparison makes the November report important for tracking cash use and clinical development spending.

Price stays near its yearly low

Corbus closed at USD 4.52 on Nasdaq on October 16, 2026 at 4:00 p.m. ET. The session range was USD 4.22 to USD 4.72, while the 52-week range stretched from USD 4.22 to USD 20.56. The closing price was 78.02 percent below the 52-week high and 7.11 percent above the 52-week low. Trading volume reached 994,935 shares, versus an average volume of 825,098 shares.

Valuation and upcoming date

Market capitalization stood at USD 87.4 million on October 16, 2026. The trailing price-to-earnings ratio was minus 0.70, reflecting the recent loss, and no dividend yield was reported. The next earnings report is scheduled for November 11, 2026, according to EarningsToday.

Comparison with peers

Corbus Pharmaceuticals (Nasdaq, USD): plus 4.39 percent, P/E minus 0.70, market capitalization USD 87.4 million
Vanda Pharmaceuticals (Nasdaq, USD): minus 4.95 percent, market capitalization USD 256.36 million
Fortress Biotech (Nasdaq, USD): minus 2.09 percent, market capitalization USD 63.7 million

Market position

Corbus Pharmaceuticals is a clinical-stage biotechnology company developing therapies for oncology and obesity. Its pipeline includes CRB-701, CRB-601 and CRB-913, with clinical milestones remaining central to the company's valuation.

Corbus Pharmaceuticals stock stood at USD 4.52 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, up 4.39 percent versus the Nasdaq prior close of USD 4.33.